EUPRAXIA PHARMACEUTICALS INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$38.61 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-03-13
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2025-12-31 | -$38.61M 40-F · filed 2026-03-13 |
| 2024-12-31 | -$25.74M 40-F · filed 2026-03-13 |
| 2023-12-31 | -$28.97M 40-F · filed 2025-03-20 |
| 2022-12-31 | -$18.99M 40-F · filed 2024-04-01 |